Central India Chronicle

Psoriatic Arthritis Pipeline: Therapeutic Assessment, Emerging Drugs, Clinical Trials, and Growth Prospects | Key Players – Pfizer, AbbVie, Sun Pharma, UCB Biopharma, and Bristol-Myers Squibb

 Breaking News
  • No posts were found

Psoriatic Arthritis Pipeline: Therapeutic Assessment, Emerging Drugs, Clinical Trials, and Growth Prospects | Key Players – Pfizer, AbbVie, Sun Pharma, UCB Biopharma, and Bristol-Myers Squibb

January 12
20:40 2022
Psoriatic Arthritis Pipeline: Therapeutic Assessment, Emerging Drugs, Clinical Trials, and Growth Prospects | Key Players - Pfizer, AbbVie, Sun Pharma, UCB Biopharma, and Bristol-Myers Squibb
Delveinsight Business Research LLP
“Psoriatic Arthritis Pipeline Insight, 2021″ report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the Psoriatic Arthritis Market.

The Psoriatic Arthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Psoriatic Arthritis Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Psoriatic Arthritis with aggregate therapies developed by each company for the same.

  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Psoriatic Arthritis Treatment.

  • Psoriatic Arthritis key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • Psoriatic Arthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Psoriatic Arthritis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Psoriatic Arthritis Therapeutics Landscape

Diversity in clinical features often makes it challenging for healthcare practitioners to distinguish from other forms of arthritis. Delayed diagnosis of PsA is associated with irreversible disease progression and poor treatment outcomes which severely affect the quality of life of patients.

The current practice relies on the individualizing choice of treatment by matching the most severely affected domains of the patients with the best available evidence of efficacies of drugs for those domains. When patients do not respond to treatment, shifting and cycling through different options would be the rational steps.

To provide effective therapeutics options, globally, several key companies are actively working to develop new therapies for the treatment of Psoriatic Arthritis. The launch of the emerging therapies is expected to change the treatment dynamics in the coming years.

Some of the key companies in the Psoriatic Arthritis Market include:

  • Pfizer

  • AbbVie

  • Sun Pharma

  • UCB Biopharma

  • Bristol-Myers Squibb

And many others.

Download Sample Pages @ Psoriatic Arthritis Therapeutics Assessment

Psoriatic Arthritis therapies covered in the report include:

  • Skyrizi

  • Ilumya (tildrakizumab-asmn)

  • Deucravacitinib

  • Rinvoq

  • Bimekizumab

  • Brepocitinib

And many more.

Request for Sample Pages @ Psoriatic Arthritis Emerging Therapies and Key Companies

Table of Content

1. Report Introduction

2. Psoriatic Arthritis 

3. Psoriatic Arthritis Current Treatment Patterns

4. Psoriatic Arthritis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Psoriatic Arthritis Late Stage Products (Phase-III)

7. Psoriatic Arthritis Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Psoriatic Arthritis Discontinued Products

13. Psoriatic Arthritis Product Profiles

14. Psoriatic Arthritis Key Companies

15. Psoriatic Arthritis Key Products

16. Dormant and Discontinued Products

17. Psoriatic Arthritis Unmet Needs

18. Psoriatic Arthritis Future Perspectives

19. Psoriatic Arthritis Analyst Review  

20. Appendix

21. Report Methodology

*The table of contents is not exhaustive; the final content may vary. 

Visit to get the sample report: https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/malignant-mesothelioma-market

Related Articles